Calyx, renowned for its Medical Imaging services and IRT/RTSM solutions, and Invicro, a prominent quantitative imaging biomarker company, have agreed to merge their operations. This strategic alliance aims to create a premier global provider of medical imaging solutions and development services for the clinical research community.

Under this agreement, Calyx will acquire 100% ownership of Invicro from REALM IDx, Inc., subject to regulatory approvals and standard closing conditions, expected to finalize in Q2 2024. With a presence across ten sites in the US, Europe, and Asia and a workforce of around 2,000 professionals, the combined entity will offer a comprehensive range of solutions to clients worldwide.

The merger capitalizes on the complementary services of Calyx and Invicro, both serving leading pharma and biotech companies globally. Together, the Group brings extensive experience, supporting nearly 12,000 clinical and research trials across various therapeutic areas, including oncology and the central nervous system (CNS). Furthermore, the integrated company will offer robust research and development capabilities to support clients throughout the preclinical and exploratory stages.

This consolidation of expertise presents a compelling value proposition for the biopharma industry, catering to a diverse range of clients from large pharmaceutical companies to specialty biotechs. The Group's services cover the entire R&D lifecycle, from discovery to post-marketing activities, including imaging biomarkers, core lab services, analytics, and software solutions.

Following the transaction's completion, the focus will be on seamlessly integrating the two companies to ensure the continued delivery of high-quality services and support to customers familiar with both Calyx and Invicro's excellence.

Souce: prnewswire.com

Report Abuse